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Vimentin, nuclear factor-kB (NF-kB) p105, fascin, E-cadherin, TGF-b, Par6 and atypical PKC are molecular markers that play an
important role in cell differentiation. Herein, we investigate their prognostic impact in primary non-small-cell carcinoma (NSCLC).
Tumour tissue samples from 335 resected patients with stage I–IIIA were used. Tissue microarrays were constructed from duplicate
cores of both neoplastic cells and stromal cells and were immunohistochemically evaluated. In univariate analyses, high tumour
epithelial cell expressions of NF-kB p105 (P¼0.02) and E-cadherin (P¼0.03) were positive prognostic indicators for disease-specific
survival (DSS), whereas high tumour epithelial cell expression of vimentin (P¼0.001) was a negative prognostic indicator. High
expression of NF-kB p105 (P¼0.001) and Par6 (P¼0.0001) in the stromal compartment correlated with a good prognosis. In
multivariate analyses, the tumour epithelial cell expression of NF-kB p105 (P¼0.0001) and vimentin (P¼0.005) and the stromal cell
expression of NF-kB p105 (P¼0.007) and Par6 (P¼0.0001) were independent prognostic factors for DSS. High expression of
NF-kB p105 and low expression of vimentin in tumour epithelial cells are independent predictors of better survival in primary
NSCLC. In stromal cells, high expressions of NF-kB p105 and Par6 are both favourable independent prognostic indicators.
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Regarded as a rare malignancy as recently as 1945, lung cancer is
now the most common cause of cancer death worldwide, with an
estimated annual incidence of more than 1.2 million cases and a
mortality of more than 1.1 million cases per year (Jemal et al,
2002). Despite recent advances in chemotherapy, radiation therapy
and surgery, the overall survival for lung cancer patients is still less
than 15%. This is particularly related to the large population with
advanced stage of disease at diagnosis and the poor treatment
effects in metastatic disease (Toloza and D’Amico, 2005). Non-
small-cell carcinoma (NSCLC) accounts for at least 80% of all lung
tumours (Ihde and Minna, 1991) and is subdivided into four major
histological groups: squamous cell carcinoma (SCC), adenocarci-
noma (AC), bronchioalveolar carcinoma (BAC) and large-cell
carcinoma (LCC) (Travis et al, 2004).
A major part of patients diagnosed with cancer die as a result of
cancer metastases resistant to conventional therapy (Fidler, 2002),
yet the mechanisms regulating tissue changes from benign to
invasive and finally to metastatic carcinoma remain fairly vague
(Chaffer et al, 2006). A better understanding of these mechanisms
will yield major contributions for improving both diagnostic and
therapeutic procedures. A range of mechanisms used by oncogenes
or tumour suppressor genes during malignant transformation has
been revealed. Some of these are accompanied by morphological
changes.
Herein, we investigate the expression of a panel of seven
markers associated with tumorigenesis in NSCLC both in epithelial
tumour cells and in tumour stroma. Our study included the
phosphorylated nuclear factor-kB (NF-kB) subunit p105 (NF-kB
p105), vimentin, E-cadherin, atypical PKC (aPKC), Par6, fascin and
transforming growth factor-b (TGF-b). Their prognostic value has
been assessed using high-throughput tissue microarray (TMA)
analyses.
PATIENTS AND METHODS
Patients and clinical samples
Primary tumour tissues from anonymised patients diagnosed with
NSCLC pathologic stage I–IIIA (Greene et al, 2002) at the
University Hospital of North Norway (UNN) and Nordland Central
Hospital (NLSH) from 1990 through 2004 were used in this study.
In total, 371 patients were registered from the hospital database.
Of these, 36 patients were excluded from the study due to
(i) radiotherapy or chemotherapy before surgery (n¼10); (ii)
other malignancies within 5 years before the NSCLC diagnosis
(n¼13); and (iii) inadequate paraffin-embedded fixed tissue
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sblocks (n¼13). Thus, 335 patients with complete medical records
and adequate paraffin-embedded tissue blocks were eligible.
This report includes follow-up data as of 30 September 2005. The
median follow-up was 96 (range 10–179) months. Complete
demographic and clinical data were collected retrospectively.
Formalin-fixed and paraffin-embedded tumour specimens were
obtained from the archives of the Departments of Pathology at UNN
and NLSH. The tumours were staged according to the International
Union Against Cancer’s TNM classification and histologically
subtyped and graded according to the World Health Organization
(Travis et al, 2004). Regarding N status, ipsilateral peribronchial or
hilar nodes and intrapulmonary nodes are defined as N1, whereas
N2 includes ipsilateral mediastinal or subcarinal nodes.
Microarray construction
All lung cancer cases were histologically reviewed by two
pathologists (SAS and KAS), and the most representative areas
of viable invasive carcinoma tissue (epithelial cells) and surround-
ing tumour stroma from central parts within the tumour were
carefully selected and marked on the haematoxylin and eosin
slides and sampled for the TMA blocks. The TMAs were assembled
using a tissue-arraying instrument (Beecher Instruments, Silver
Springs, MD, USA). The detailed methodology has been reported
earlier (Bremnes et al, 2006).
TMA represents a practical tool for studying a large number of
biological markers that may have significant therapeutic effects.
Studying whole tissue sections is, however, still needed to increase
the value of the TMA results before therapeutical implementation.
Briefly, we used a 0.6-mm diameter stylet, and the study specimens
were routinely sampled in duplication from epithelial cancer cells
and from tumour-surrounding stroma intervening malignant
epithelial areas. Normal lung tissue localised distant from the
primary tumour were used as negative controls.
To include all core samples, eight tissue array blocks were
constructed. Multiple 5-mm sections were cut with a Micron
microtome (HM355S) and stained by specific antibodies for
immunohistochemistry (IHC) analysis.
Immunohistochemistry
The applied antibodies had been subjected to in-house validation
by the manufacturer for IHC analysis on paraffin-embedded
material. For the antibodies used in the study, see Table 1. For
staining with fascin and NF-kB p105, sections were deparaffinised
with xylene and rehydrated with ethanol. Antigen retrieval was
performed by placing the specimen in 0.01moll
 1 citrate buffer at
pH 6.0 and exposed to two repeated microwave heatings of 10min
at 450W. The DAKO EnVisionþSystem-HRP (DAB) kit was used
for endogen peroxidase blocking. Primary antibodies for fascin
and NF-kB p105 were incubated for 30min at room temperature.
For staining with the remaining antibodies, the slides were
transferred to the Ventana Benchmark, XT automated slide stainer
(Ventana Medical System, Illkirch, France). The DAKO En-
Visionþ System-HRP (DAB) kit was used to visualise the antigens
for all stains. This yielded a brown reaction product at the site of
the target antigen. Tissue sections were incubated with primary
antibodies recognising vimentin, E-cadherin, Par6, aPKC and TGF-
b. Primary antibodies were incubated at 371C (vimentin 24min,
E-cadherin 32min, aPKC 28min, Par6 52min and TGF-b 28min).
As negative staining controls, the primary antibodies were
replaced with the primary antibody diluent. Finally, all slides were
counterstained with haematoxylin to visualise the nuclei. For each
antibody, including negative controls, all TMA stainings were
performed in a single experiment (Figure 1).
Table 1 Antibodies
Antigen Antibody Clone Catalogue no. Source Dilution
NF-kB p105 Rabbit monoclonal 178F3 4808S Cell Signaling Technology (Danvers, MA, USA) 1:50
Vimentin Mouse monoclonal V9 790–2917 Ventana Medical Systems (Illkirch, France)
a
E-cadherin Mouse monoclonal ECH-6 760–2830 Cell Marque (Rocklin, CA, USA)
a
Par6 Rabbit polyclonal H90 Sc-25525 Santa Cruz Biotechnology (Santa Cruz, CA, USA) 1:10
aPKC Rabbit polyclonal C20 Sc-216 Santa Cruz 1:100
Fascin Mouse monoclonal 55K2 MAB3582 Chemicon International (Temecula, CA, USA) 1:25
TGF-b Rabbit polyclonal V Sc-146 Santa Cruz 1:50
aPKC¼atypical protein kinase C; NF-kB¼nuclear factor-kB; Par6¼partitioning-defective protein-6.
aPre-diluted from the manufacturer.
E-cadherin Fascin Vimentin
Decreased
epithelial differentiation
NF-B
AKT/PKB
RAS aPKC
Par6
RTK
TGF-R
TGF-
Risk factors
A
B
C
Figure 1 Simplified schematic illustration of signals regulating cell
differentiation. (A) Polarised normal epithelium cells with tight junctions
between cells resting on the basement membrane. (B) Different risk
factors (including cigarette smoke, toxins and genetic factors) can cause
activation of different oncogenes, which regulate cell differentiation.
Activation of receptor tyrosine kinases (RTKs) is known to play a role in
inducing mesenchymal phenotype. (C) Unpolarised spindle-shaped
epithelial cells with loss of tight junctions and upregulation of mesenchymal
markers like vimentin and fascin. TGF-b¼transforming growth factor-b;
TGF-bR¼transforming growth factor-beta receptor; RAS¼rat sarcoma
oncogene; NF-kB¼nuclear factor-kB; AKT/PKB¼AKT/protein kinase B;
Par6¼partitioning-defective protein-6; aPKC¼atypical protein kinase C.
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sScoring of IHC
By light microscopy, representative viable tissue sections were
scored semiquantitatively for cytoplasmic or membranous staining
(Figure 2). The dominant staining intensity in both tumour
epithelial cells and stromal cells was scored as 0¼negative;
1¼weak; 2¼intermediate; and 3¼strong. The cell density of the
stroma was scored as 1¼low density; 2¼intermediate density;
and 3¼high density. All samples were anonymised and indepen-
dently scored by two pathologists (SAS and KAS). In case of
disagreement, the slides were re-examined and a consensus was
reached by the observers. When assessing one variable for a given
core, the observers were blinded to the scores of the other variables
and to outcome. To evaluate the interobserver agreement with
respect to IHC scoring, 100 consecutive tumour epithelial cell cores
and tumour stroma cores, stained for two rabbit polyclonal
markers (VEGF-C and VEGFR-3), were examined (Donnem et al,
2007). The mean correlation coefficient (r) was 0.95 (range 0.93–
0.98) and was assessed for both antibodies in both tumour
epithelial and stromal areas.
Mean score for duplicate cores from each individual was
calculated separately in tumour epithelial cells and stroma, and a
high expression in tumour epithelial cells was defined as score X2.
Stromal expression was calculated by summarising density score
(1–3) and intensity score (0–3) before categorising into low
and high expression. High expression in stroma was defined as
score X4.
Statistical methods
All statistical analyses were performed using the statistical package
SPSS (Chicago, IL, USA), version 14. The w
2 test and Fisher’s Exact
test were used to examine the association between molecular
marker expression and various clinicopathological parameters.
Univariate analysis was performed by using the Kaplan–Meier
method, and statistical significance between survival curves was
assessed by the log rank test. Disease-specific survival (DSS) was
determined from the date of surgery to the time of lung cancer
death. To assess the independent value of different pre-treatment
variables on survival, in the presence of other variables, multi-
variate analysis was carried out using the Cox proportional
hazards model. Only variables of significant value from the
univariate analysis were entered into the Cox regression analysis.
Probability for stepwise entry and removal was set at 0.05 and 0.1,
respectively.
Ethics clearance
The National Data Inspection Board and The Regional Committee
for Research Ethics approved the study.
RESULTS
Patient data
Demographical, clinical and histopathological variables are shown
in Table 1. The median age was 67 years (range 28–85) and 75% of
the patients were male individuals. The patient population of 335
cases represented the four major subtypes of NSCLC with 191
SCCs, 95 ACs, 31 LCCs and 18 BACs. Owing to nodal metastases or
non-radical surgical margins, 18% (59 patients) received post-
operative radiotherapy.
Expression pattern and correlations with
clinicopathological variables
Our IHC analyses included the phosphorylated NF-kB p105,
vimentin, E-cadherin, aPKC, Par6, fascin and TGF-b. All the
investigated markers except E-cadherin were expressed in the
cytoplasm of tumour epithelial cells. E-cadherin showed a
membranous staining. On the basis of morphological criteria,
pneumocytes in control cores from normal lung tissue, distant
from the primary tumour, generally showed weak positive
immunostaining.
Par6
in stroma cells
NF-B p105
in stroma cells
E-cadherin
in tumour
NF-B p105
in tumour
A
B
C
D
Figure 2 Immunohistochemical analysis of TMA of NSCLC representing
different EMT markers including (A) NF-kB p105 and (B) E-cadherin
in tumour as well as (C) NF-kB p105 and (D) Par6 in stromal cells.
NF-kB¼nuclear factor-kB; NSCLC¼non-small-cell carcinoma; TMA¼
tissue microarray.
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sTable 2 Prognostic clinicopathological variables as predictors for
disease-specific survival in 335 NSCLC patients (univariate analysis;
log-rank test)
Characteristics
Patients
(n)
Patients
(%)
Median
survival
(months)
5-year
survival
(%) P-value
Age (years)
p65 156 47 104 57 0.62
465 179 53 NR 58
Sex
Female 82 25 127 65 0.19
Male 253 75 84 55
Smoking
Never 15 5 19 43 0.13
Present 215 64 NR 60
Previous 105 31 84 54
Performance status
Normal 197 59 NR 62 0.04
Slightly reduced 120 36 61 52
In bed o50% 18 5 36 40
Weight loss
o10% 303 90 127 57 0.92
410% 32 10 NR 57
Histology
SCC 191 57 NR 65 0.30
Adenocarcinoma 95 28 52 44
BAC 18 5 NR 67
LCC 31 9 84 54
Differentiation
Poor 138 41 48 48 0.001
Moderate 144 43 NR 64
Well 53 16 NR 65
Surgical procedure
Lobectomy+wedge
a 243 73 NR 61 0.0009
Pneumonectomy 92 27 35 46
Stage
I 212 63 NR 68 o0.0001
II 91 27 41 46
IIIa 32 10 18 22
Tumour status
1 90 27 NR 75 0.002
2 218 65 84 52
3 27 8 42 43
Nodal status
0 232 69 NR 66 o0.0001
17 6 2 3 3 7 4 3
2 27 8 18 20
Surgical margins
Free 307 92 127 58 0.34
Not free 28 8 64 51
Vascular infiltration
No 284 85 NR 61 0.0005
Yes 51 15 25 35
Postoperative radiotherapy
No 276 82 NR 61 0.002
Yes 59 18 41 42
BAC¼bronchioalveolar carcinoma; LCC¼large-cell carcinoma; NR¼not reached;
NSCLC¼non-small-cell carcinoma; SCC¼squamous cell carcinoma.
aWedge,
n¼10.
Table 3 Tumour epithelial cell and stromal cell expression of markers
associated with mesenchymal phenotype as predictors for disease-specific
survival in 335 NSCLC patients (univariate analysis; log-rank test)
Marker expression
Patients
(n)
Patients
(%)
Median
survival
(months)
5-year
survival
(%) P-value
NF-kB p105
Tumour 0.019
Low 176 52 NR 53
Moderate 124 37 71 56
High 33 10 NR 85
Missing 2 1
Stroma 0.001
Low 248 74 71 53
High 86 25 NR 72
Missing 1 1
Vimentin
Tumour 0.001
Negative 244 73 NR 62
Low 58 17 84 66
High 28 8 22 33
Missing 5 2
Stroma 0.297
Low 90 27 104 54
High 242 72 NR 59
Missing 3 1
E-cadherin
Tumour 0.025
Low 120 36 61 51
High 201 60 NR 62
Missing 14 4
Stroma
Negative for staining
Par6
Tumour 0.73
Low 169 51 NR 59
High 162 48 84 57
Missing 4 1
Stroma 0.0001
Low 117 35 37 43
High 216 64 NR 66
aPKC 21
Tumour 0.154
Low 54 16 NR 66
High 278 83 84 56
Missing 3 1
Stroma
Negative for staining
Fascin
Tumour 0.422
Low 96 28 29 53
High 235 70 NR 60
Missing 4 1
Stroma
Negative for staining
TGF-b
Tumour 0.128
Low 270 81 104 55
High 61 18 NR 69
Missing 4 1
Stroma
Negative for staining
aPKC¼atypical protein kinase C; NF-kB¼nuclear factor-kB; NSCLC¼non-small-
cell carcinoma; Par6¼partitioning-defective protein-6.
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(macrophages, lymphocytes, granulocytes and plasma cells) and
endothelial cells frequently showed positive staining for NF-kB
p105, vimentin and Par6, whereas fibroblast-like cells only
occasionally presented positive staining. No stromal cell staining
was observed for E-cadherin, fascin, TGF-b and aPKC.
Expression of the investigated markers in tumour epithelial cells
or stroma did not correlate with clinical performance status,
vascular infiltration or histological subgroups. Expression of
vimentin and Par6 in tumour epithelial cells correlated signifi-
cantly (r¼0.2, Po0.001), as did vimentin and tumour differentia-
tion (r¼ 0.1, P¼0.01). High expression of vimentin was seen in
61% of poorly differentiated tumours, 39% of moderately
differentiated tumours and no expression was seen in well-
differentiated tumours. Even among the patient group with poorly
differentiated tumours, high tumour epithelial cell vimentin
expression tended to correlate with poor survival (P¼0.08).
Further, a significant correlation was seen between tumour
epithelial expression of aPKC and Par6 (r¼0.2, Po0.001).
Univariate analysis
In addition to the statistically significant clinical variables
(Table 2), tumour epithelial cell expression of NF-kB p105
(P¼0.02), vimentin (P¼0.001) and E-cadherin (P¼0.03), and
stromal cell expression of NF-kB p105 (P¼0.001) and Par6
(P¼0.0001) were prognostic indicators for DSS in univariate
analyses (Table 3; Figures 3 and 4). Stratifying the cases based on
histology revealed that the significance of better survival for high
tumour epithelial NF-kB p105 and vimentin expression was
limited to ACs (P¼0.03 and P¼0.0004, respectively) and stromal
NF-kB p105 and Par6 expression to SCCs (P¼0.001 and
P¼0.0009, respectively). There was no significant association
between DSS and tumour epithelial cell expression of aPKC
(P¼0.2), Par6 (P¼0.7), fascin (P¼0.4), TGF-b (P¼0.1) or
stromal cell expression of vimentin (P¼0.3) (Table 3).
Multivariate Cox proportional hazards analysis
All significant clinicopathological and molecular variables from
the univariate analyses were entered into the multivariate analysis.
Data are presented in Table 4. Tumour epithelial cell expression of
NF-kB p105 (P¼0.001) and vimentin (P¼0.005), stromal cell
expression of NF-kB p105 (P¼0.007) and Par6 (P¼0.0001), and
the clinicopathological variables T stage (P¼0.02), N stage
(P¼0.0001) and performance status (P¼0.03) were all indepen-
dent prognostic factors for survival. High tumour epithelial cell
expression of E-cadherin (P¼0.05), histological differentiation
(P¼0.05) and vascular infiltration (P¼0.06) tended towards a
statistical significance.
DISCUSSION
Using high-throughput TMA analyses, an established method for
assessing protein expression across large sets of lung cancer tissues
(Bremnes et al, 2002), we sought to determine the prognostic
impact of a panel of seven molecular markers associated with
tumorigenesis. High stromal expression of NF-kB p105 and Par6 as
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Figure 4 Disease-specific survival curves for stromal NF-kB p105 and Par6. NF-kB¼nuclear factor-kB; Par6¼partitioning-defective protein-6.
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Figure 3 Disease-specific survival curves for tumour epithelial cell NF-kB p105, vimentin and E-cadherin. NF-kB¼nuclear factor-kB.
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swell as high epithelial tumour cell expression of NF-kB p105
showed an independent positive correlation with DSS. In contrast,
vimentin expression in tumour epithelial cells was an independent
negative prognostic indicator for DSS.
Immunohistochemistry as a method for detecting protein
expression in paraffin-embedded tissue has been shown to be
both highly sensitive and specific (Zafrani et al, 2000), yet the
specificity of an immunohistochemical test would never exceed the
specificity of the antibody provided by the manufacturer. Never-
theless, an additional possible source of error can still be the
biological variation of protein expression in different areas of
tumour tissue. Nonetheless, this source of bias can be reduced by
increasing the number of examined tissue as in this study.
Stromal–epithelial interactions are considered critical for
regulating tissue development and for the maintenance of tissue
homoeostasis (Kass et al, 2007). Consequently, it seems essential
also to study the tumour stroma and its different molecular
markers to be able to understand the mechanism of tumour
metastases. In this study, the term ‘stroma’ comprises all groups of
non-epithelial cells and structures intervening between islands of
tumour epithelial cells, that is mesenchymal cells (fibroblasts and
fibroblast-like cells), leukocytes, macrophages, endothelial cells
and extracellular matrix (ECM) including collagen. Investigating
the stromal compartment can, however, be complicated as the
stroma is not static. Cellular and ECM compositions evolve over
time, adapting to changes related to the surrounding epithelial
cells (Kass et al, 2007).
Stromal cells appear, in some instances, to support growth and
motility of tumour cells (Costea et al, 2006), and in other instances
to be part of the microenvironment in preventing tumour cell
invasion, in concert with the assumed function of the immune
system. Thus, stromal cells have rather complex and controversial
roles during the ‘abnormal’ condition of tumorigenesis. Hence, it is
of great interest that a high stromal expression of NF-kB p105 and
Par6 correlates favourably with patient survival.
Nuclear factor-kB is a group of proteins that control inflamma-
tion, cell survival, transformation, proliferation, angiogenesis and
apoptosis (Aggarwal, 2004). It is normally retained in the
cytoplasm in an inactive state through interaction with inhibitor
kB( I kB) (Karin et al, 2002). Degradation of the IkB proteins
results in the liberation of NF-kB, allowing nuclear translocation
and the activation of target genes, including Snail and Bcl-2
(Guarino, 2007). NF-kB is activated in a range of human cancers
and is assumed to promote tumorigenesis (Radisky and Bissell,
2007). Five mammalian NF-kB proteins have been identified: p65
(RelA), NF-kB1 (p50 and its precursor p105), NF-kB2 (p52 and its
precursor p100), c-rel and RelB (Ghosh et al, 1990). These bind to
DNA as homo- or heterodimers.
Havard et al (2005) observed high levels of NF-kB p105
precursor in cell lines derived from human cervical cancers
associated with HPV16 infection and in keratinocytes transfected
by oncogenes. In another study, Ishikawa et al (1998) observed
that NF-kB p105 /  mice showed abnormalities such as
inflammation in lungs and liver, myeloid hyperplasia in bone
marrow and splenomegaly (Weih et al, 1994). In a study that
included 45 patients with NSCLC, Zhang et al (2006) found
overexpression of NF-kB p50 to indicate an unfavourable overall
survival in NSCLC patients. To our knowledge, the prognostic
significance of the precursor NF-kB p105 in both tumour epithelial
and stromal cells of NSCLC has hitherto not been reported. In our
study, NF-kB p105 expressions in both tumour epithelial and
stromal cells were favourable independent prognostic indicators
for survival.
Par6 and aPKC have emerged as central players in the regulation
of cell polarity and the asymmetric division of cells (Etienne-
Manneville and Hall, 2003). Par6 is an adapter protein that engages
in many protein–protein interactions regulated to control cell
polarity (Thiery and Huang, 2005). In previous cancer cell line
studies, Regala et al (2005) categorised aPKC-iota as an oncogene
in NSCLC. Through PubMed searches, we could not identify
studies investigating the prognostic significance of Par6 and aPKC-
iota expression in resected primary NSCLC tissues. In this study,
we found high Par6 stromal cell expression to be associated with
an improved prognosis, whereas tumour epithelial cell expression
of Par6 and aPKC-iota did not show any prognostic relevance.
These results indicate that an observed significance of protein
expression in cell lines in vitro does not necessarily have the same
impact in vivo. The interplay with the ECM may be essential in
explaining the discrepancy of these results.
Cadherin-mediated cell–cell adhesion is considered a suppressor
of cancer cell invasion in vitro (Behrens et al, 1993). Loss of
E-cadherin has previously been attributed to an unfavourable
prognostic significance in bladder cancer (Baumgart et al, 2007).
Low E-cadherin expression in NSCLC tumours has been reported
in several studies (Liu et al, 2001) to be associated with a more
‘aggressive’ behaviour of tumour epithelial cells and with a worse
Table 4 Results of Cox regression analysis summarising significant
independent prognostic factors
Factors Hazard ratio 95% CI P-value
Tumour status 0.022
a
1 1.000
2 1.822 1.080–3.072 0.025
3 2.681 1.278–5.626 0.009
Nodal status 0.0001
a
0 1.000
1 1.942 1.237–3.048 0.004
2 2.874 1.566–5.276 0.001
Performance status 0.034
a
Normal 1.000
Slightly reduced 1.696 1.139–2.526 0.009
In bed o50% 1.298 0.503–3.350 0.590
Differentiation 0.053
a
Poor 1.000
Moderate 1.473 0.783–2.770 0.230
Well 0.875 0.459–1.669 0.685
Vascular infiltration
No 1.000
Yes 1.603 0.975–2.636 0.063
NF-kB p105 tumour 0.001
a
High 1.000
Moderate 8.986 2.821–28.629 0.0001
Low 7.117 2.182–23.214 0.001
NF-kB p105 stroma
High 1.000
Low 2.164 1.231–3.806 0.007
Vimentin tumour 0.005
a
High 2.695 1.441–5.039 0.002
Moderate 0.892 0.529–1.504 0.667
Negative 1.000
E-cadherin tumour 0.052
a
High 1.000
Low 1.467 0.997–2.158
Par6 stroma 0.0001
a
High 1.000
Low 2.458 1.660–3.640 0.0001
CI¼confidence interval.
aOverall significance as a prognostic factor.
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epithelial cells are consistent with these findings.
We further examined the significance of fascin and vimentin
expression in NSCLC. Fascin is an actin-bundling and crosslinking
protein that binds to preformed filaments and regulates their
organisation and stability. It is presumed to regulate cortical cell
membrane protrusions (Kureishy et al, 2002). Its overexpression is
proposed to increase the motility of epithelial cells (Adams, 2004).
The available data on fascin expression and its significance in NSCLC
are scarce. In a recent study by Pelosi et al (2003) in 220 stage I
NSCLC patients, high tumour cell expression of fascin emerged as an
independent predictor of lymph node metastases and poor survival.
Our data did not, however, show any correlation between tumour
expression of fascin and lymph node metastases or survival.
Vimentin is a structural protein from cells of mesenchymal origin
(Leader et al, 1987). Its expression is higher in migratory epithelial
cells and may contribute to the migratory and invasive phenotype of
metastatic cells (Bindels et al, 2006). Significant correlations
between high vimentin tumour cell expression and poor prognosis
have previously been reported both in hepatocellular (Hu et al,
2004) and breast carcinoma (Dandachi et al, 2001). Consistent with
the latter reports, we found high tumour epithelial cell vimentin
expression to be an independent prognosticator for poor survival in
resected NSCLC patients. In contrast, Pelletier et al (2001) in 113
resected NSCLC patients found no such correlation.
Transforming growth factor-b is a multifunctional cytokine that
plays a central role in signalling networks regulating cell growth,
differentiation, adhesion and apoptosis, and is one of the most
potent and better-studied markers inducing mesenchymal pheno-
type in epithelial cells (Janda et al, 2002). There are indications
that TGF-b-dependent loss of tight junctions is mediated through
Par6 phosphorylation by the TGF-b receptor and is probably
independent of Smad-mediated transcriptional responses
(Ozdamar et al, 2005). In a recent study, von Rahden et al
(2006) observed a correlation between high TGF-b tumour cell
expression and a poor prognosis in oesophageal AC. In NSCLC
tumours (Boldrini et al, 2000; Hasegawa et al, 2001; Saji et al,
2003), there are conflicting data regarding associations between
TGF-b expression and survival. In this study, no significant
association was seen between TGF-b tumour cell expression and
overall survival.
In summary, we detected an unanticipated behaviour of
tumour stromal cells and their impact on survival. Hence, the
interaction between tumour stromal cells and tumour epithelial
cells plays an important role in the process of cell invasion
and metastases, yet many nuances of this interaction are still not
clear. Our data give rise to additional investigation, which
may provide the foundation for generating more effective
therapeutic strategies not only in NSCLC but also in other
malignancies.
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